EUVIMEDEUVIMED entdecken
Open Access

Glioma–astrocyte connexin43 confers temozolomide resistance through activation of the E2F1/ERCC1 axis

Yanping Gui, Hongkun Qin, Xinyu Zhang, Qianqian Chen, Fangyu Ye, Geng Tian, Shihe Yang, Yuting Ye, Di Pan, Jieying Zhou, Xiangshan Fan, Yajing Wang und 1 weitere

Neuro-Oncology · 07.03.2025 · 27 (3) · 711-726

DOI: 10.1093/neuonc/noae237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 08.11.2024. Verfasst von Yanping Gui und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, P.R. China. Hauptthemen laut MEDLINE: Temozolomide, Connexin 43, Drug Resistance, Neoplasm, Glioma. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioma is the most prevalent and lethal tumor of the central nervous system. Routine treatment with temozolomide (TMZ) would unfortunately result in inevitable recurrence and therapy resistance, severely limiting therapeutic efficacy. Tumor-associated astrocytes (TAAs) are key components of the tumor microenvironment and increasing evidence has demonstrated that aberrant expression of connexin43 (Cx43) was closely associated with glioma progression and TMZ resistance. However, the specific role of Cx43 in mediating TMZ resistance through glioma and astrocyte interactions has not been fully explored.

Methods

The expression and prognostic value of Cx43 were evaluated in tumor samples and clinical databases. ShRNA-medicated knockdown and Gfap-Cre Cx43flox/flox gene mouse were used to assess the role and functional significance of Cx43 in vitro and in vivo. Moreover, we performed mass spectrometry analysis, chromatin immunoprecipitation, and other biochemical assays to define the molecular mechanisms by which Cx43 promotes TMZ resistance.

Results

We confirmed that the upregulation of Cx43 expression between TAAs and glioma cells contributed to TMZ resistance and tumor recurrence. Genetic knockdown or pharmacological inhibition of Cx43 enhanced TMZ-induced cytotoxicity. Mechanistically, elevated Cx43 expression induced β-catenin accumulation at the cell surface of glioma cells, suppressing T-cell factor/lymphoid enhancer-binding factor transcription. This led to impaired miR-205-5p expression and subsequent activation of the E2F1/ERCC1 axis, which eventually led to chemoresistance.

Conclusions

Our study reveals a novel regulatory mechanism in which the Cx43/miR-205-5p/E2F1/ERCC1 axis contributes to TMZ resistance in glioma. These findings further highlight the potential of targeting Cx43 as a therapeutic strategy in glioma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideConnexin 43Drug Resistance, NeoplasmGliomaBrain NeoplasmsAntineoplastic Agents, AlkylatingAstrocytesE2F1 Transcription FactorAnimalsHumansMicePrognosisTumor Cells, CulturedGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

Connexin 43ERCC1drug resistancegliomatemozolomide

Substanzen

TemozolomideConnexin 43Antineoplastic Agents, AlkylatingE2F1 Transcription FactorE2F1 protein, humanGJA1 protein, human

Autor:innen und Institutionen

  • School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, P.R. China.
  • Public Experimental Platform, China Pharmaceutical University, Nanjing, P.R. China.
  • The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, P.R. China.
  • Department of Chemistry and Biochemistry, Florida International University, Miami, Florida.
  • Department of Pathology, Affiliated Nanjing Drum Tower Hospital of Nanjing University School of Medicine, Nanjing, P.R. China.

ORCID-Profile: Li Zhao

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Gui, Y., Qin, H., Zhang, X., Chen, Q., Ye, F., Tian, G., Yang, S., Ye, Y., Pan, D., Zhou, J., Fan, X., Wang, Y., & Zhao, L. (2025). Glioma–astrocyte connexin43 confers temozolomide resistance through activation of the E2F1/ERCC1 axis. Neuro-Oncology, 27(3), 711-726. https://doi.org/10.1093/neuonc/noae237

Vancouver

Gui Y, Qin H, Zhang X, Chen Q, Ye F, Tian G, et al. Glioma–astrocyte connexin43 confers temozolomide resistance through activation of the E2F1/ERCC1 axis. Neuro-Oncology. 2025;27(3):711-726. doi:10.1093/neuonc/noae237

BibTeX
@article{Gui2025,
  author = {Gui, Yanping and Qin, Hongkun and Zhang, Xinyu and Chen, Qianqian and Ye, Fangyu and Tian, Geng and Yang, Shihe and Ye, Yuting and Pan, Di and Zhou, Jieying and Fan, Xiangshan and Wang, Yajing and Zhao, Li},
  title = {Glioma–astrocyte connexin43 confers temozolomide resistance through activation of the E2F1/ERCC1 axis},
  journal = {Neuro-Oncology},
  year = {2025},
  volume = {27},
  number = {3},
  pages = {711--726},
  doi = {10.1093/neuonc/noae237}
}
Kostenlos starten →